[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

2018 Angina Pectoris Or Ischemic Chest Pain Drug Development Pipeline Analysis Report- Companies, Drugs, Clinical Trials, Latest Developments in Angina Pectoris Or Ischemic Chest Pain Market

June 2018 | 70 pages | ID: 2BB2E28E244EN
VPAResearch

US$ 999.00

E-mail Delivery (PDF)

Download PDF Leaflet

Accepted cards
Wire Transfer
Checkout Later
Need Help? Ask a Question
Angina or Angina Pectoris market is estimated to be valued around $12 billion. It occurs when the blood flowing into coronary arteries fails to provide the required oxygen volumes. The main cause of this condition is Coronary heart disease. Unlike heart attack, Angina is temporary and does not cause any damage to the heart muscles. It is often classified as stable Angina (pain exists for less than 15 minutes) and unstable Angina (pain exists for more than 15 minutes).

To assist researchers, investors and business development managers, VPA Research has come up with a comprehensive report on Angina Pectoris Or Ischemic Chest Pain pipeline. The report provides insights into different therapeutic candidates in preclinical, research, discovery, NDA/IND, pre registration, phase 1, phase 2, and phase 3 trials). Drugs under development directly and through combination with other drugs are also included.

Current status, developmental phase, participating companies and entities, recent developments, orphan drug/ fast track/ other designations, drug class are provided for each Angina Pectoris Or Ischemic Chest Pain pipeline product. Mechanism of Action and the target area of the pipeline product are also provided. Further, clinical and preclinical trials along with results of the trials are also included in the report.

In addition to complete details of each product, the report provides key trends in Angina Pectoris Or Ischemic Chest Pain pipeline studies. The products under development are categorized according to their development phase, mechanism and company to provide detailed insights into the type of drugs being developed and the stages of development.
1 TABLE OF CONTENTS

1.1 List of LIST OF FIGURES
1.2 List of Tables

2 ANGINA PECTORIS OR ISCHEMIC CHEST PAIN PIPELINE ANALYSIS

2.1 Disease and Pipeline Overview
2.2 Angina Pectoris Or Ischemic Chest Pain Pipeline Snapshot
2.3 Angina Pectoris Or Ischemic Chest Pain Pipeline by Phase
2.4 Angina Pectoris Or Ischemic Chest Pain Pipeline by Company
2.5 Angina Pectoris Or Ischemic Chest Pain Pipeline by Mechanism of Action

3 ANGINA PECTORIS OR ISCHEMIC CHEST PAIN- COMPANY WISE PIPELINE ANALYSIS

Angionetics Inc
Beijing CoSci Med-Tech Co.,Ltd
Caladrius Biosciences Inc
G. Pohl-Boskamp GmbH & Co KG
Hemostemix Inc
ID Pharma Co Ltd
Juventas Therapeutics Inc
Kuhnil Pharmaceutical Co Ltd
Sanofi S.A.
TSH Biopharm Corporation Ltd
ViroMed Co Ltd
XyloCor Therapeutics, Inc.

4 ANGINA PECTORIS OR ISCHEMIC CHEST PAIN R&D PIPELINE SNAPSHOTS

Drug wise Pipeline Details
Therapeutic Candidate Name
Originator
Co-Developer/ License Partner
Orphan Drug Designation
Development Phase
Mechanism of Action
Current Status
Ongoing Clinical Trial Details

5 RECENT DEVELOPMENTS IN ANGINA PECTORIS OR ISCHEMIC CHEST PAIN PIPELINE

6 APPENDIX

6.1 About VPA Research
6.2 Sources and Research Methodology

LIST OF FIGURES

Figure 1: Angina Pectoris Or Ischemic Chest Pain Pipeline by Phase, H2- 2018
Figure 2: Angina Pectoris Or Ischemic Chest Pain Pipeline by Companies, H2- 2018
Figure 3: Company Wise Pipeline Drug Phases, H2- 2018
Figure 4: Angina Pectoris Or Ischemic Chest Pain Pipeline by Mechanism of Action, H2- 2018
Figure 5: Mechanism Wise Pipeline Drug Phases, H2- 2018

LIST OF TABLES

Angina Pectoris Or Ischemic Chest Pain Pipeline by Phase, H2- 2018
Angina Pectoris Or Ischemic Chest Pain Pipeline by Companies, H2- 2018
Angina Pectoris Or Ischemic Chest Pain Pipeline by Mechanism of Action, H2- 2018
Table 1: Angionetics Inc Angina Pectoris Or Ischemic Chest Pain Pipeline Drugs, H2- 2018
Table 2: Beijing CoSci Med-Tech Co.,Ltd Angina Pectoris Or Ischemic Chest Pain Pipeline Drugs, H2- 2018
Table 3: Caladrius Biosciences Inc Angina Pectoris Or Ischemic Chest Pain Pipeline Drugs, H2- 2018
Table 4: G. Pohl-Boskamp GmbH & Co KG Angina Pectoris Or Ischemic Chest Pain Pipeline Drugs, H2- 2018
Table 5: Hemostemix Inc Angina Pectoris Or Ischemic Chest Pain Pipeline Drugs, H2- 2018
Table 6: ID Pharma Co Ltd Angina Pectoris Or Ischemic Chest Pain Pipeline Drugs, H2- 2018
Table 7: Juventas Therapeutics Inc Angina Pectoris Or Ischemic Chest Pain Pipeline Drugs, H2- 2018
Table 8: Kuhnil Pharmaceutical Co Ltd Angina Pectoris Or Ischemic Chest Pain Pipeline Drugs, H2- 2018
Table 9: Sanofi S.A. Angina Pectoris Or Ischemic Chest Pain Pipeline Drugs, H2- 2018
Table 10: TSH Biopharm Corporation Ltd Angina Pectoris Or Ischemic Chest Pain Pipeline Drugs, H2- 2018
Table 11: ViroMed Co Ltd Angina Pectoris Or Ischemic Chest Pain Pipeline Drugs, H2- 2018
Table 12: XyloCor Therapeutics, Inc. Angina Pectoris Or Ischemic Chest Pain Pipeline Drugs, H2- 2018


More Publications